AZD8055

Name: AZD8055
Brand: Selleck Chemicals
SKU: S1555
Rating: 5 (146 reviews)

For research use only.

Catalog No.S1555

146 publications

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

Selleck's AZD8055 has been cited by 146 publications

Nature, 2019, 10.1038/s41586-019-1607-3

PubMed: 31578521 ( click the link to review the publication )

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Nat Med, 2017, 23(2):200-212

PubMed: 28067899 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):177-190

PubMed: 27939219 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):255-63

PubMed: 25564516 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):245-54

PubMed: 25564517 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107810

PubMed: 32579936 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):107

PubMed: 32517736 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):882-894

PubMed: 31879363 ( click the link to review the publication )

J Cancer, 2020, 15;11(12):3492-3501

PubMed: 32284745 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):4025

PubMed: 32132574 ( click the link to review the publication )

J Biol Chem, 2020, 22;295(21):7418-7430

PubMed: 32312748 ( click the link to review the publication )

Biosci Rep, 2020, 30;40(4):BSR20200905

PubMed: 32285908 ( click the link to review the publication )
Biochem Biophys Res Commun, 2020, 23;S0006-291X(20)30951-7

PubMed: 32456793 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3627

PubMed: 32686664 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

Nat Med, 2020, 10.1038/s41591-020-0986-1

PubMed: 32719489 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106241

PubMed: 32058927 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 15(3):543-557

PubMed: 30269645 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5107-5121

PubMed: 31164374 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Sci Signal, 2019, 12(612)

PubMed: 31848319 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627299 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):366-377

PubMed: 30661989 ( click the link to review the publication )

Curr Biol, 2019, 29(5):737-749

PubMed: 30773367 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(9):1922-1937

PubMed: 31598395 ( click the link to review the publication )

Sci Rep, 2019, 9(1):30

PubMed: 30631106 ( click the link to review the publication )

Sci Rep, 2019, 9(1):9805

PubMed: 31285446 ( click the link to review the publication )
Cancer Gene Ther, 2019, 10.1038/s41417-019-0117-7

PubMed: 31257364 ( click the link to review the publication )

Biochem J, 2019, 476(20):3081-3107

PubMed: 31665227 ( click the link to review the publication )

Front Physiol, 2019, 10:167

PubMed: 30873046 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:5196028

PubMed: 31223619 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):21-36

PubMed: 30831322 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):465-478

PubMed: 29593330 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1063

PubMed: 30337536 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(8):1338-1346

PubMed: 29345254 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2735-2743

PubMed: 29720580 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4561-4566

PubMed: 30214591 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):632-642

PubMed: 29928450 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2207

PubMed: 29263324 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(15):2074-2084

PubMed: 27748760 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )
Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2017, 1864(10):1554-1565

PubMed: 28641977 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Anticancer Res, 2017, 37(3):1083-1090

PubMed: 28314268 ( click the link to review the publication )

Oncotarget, 2017, 8(25):41422-41431

PubMed: 28507282 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(5):527-39

PubMed: 27043084 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(1):22-8

PubMed: 26595461 ( click the link to review the publication )

EMBO J, 2016, 35(17):1902-22

PubMed: 27481935 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Oncol, 2016, 10(4):538-52

PubMed: 26686971 ( click the link to review the publication )

J Biol Chem, 2016, 291(12):6262-71

PubMed: 26755732 ( click the link to review the publication )

Front Plant Sci, 2016, 7:1746

PubMed: 27917191 ( click the link to review the publication )

Cell Signal, 2016, 28(4):284-93

PubMed: 26795954 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1515-20

PubMed: 27565731 ( click the link to review the publication )

Int J Endocrinol, 2016, 2016:5286972

PubMed: 27990160 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Autophagy, 2015, 11(2):285-97

PubMed: 25801301 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Sci Signal, 2015, 8(375):ra42

PubMed: 25943352 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )
J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: 25725958 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Clin Sci (Lond), 2015, 128(8):517-26

PubMed: 25428582 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2014, 10(6):1120-36

PubMed: 24879157 ( click the link to review the publication )

Leukemia, 2014, 28(5):1092-102

PubMed: 24135829 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(22):5756-67

PubMed: 25316808 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )
Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

Oncol Rep, 2014, 31(2):649-56

PubMed: 24297300 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

Blood, 2013, 121(18):3619-30

PubMed: 23444404 ( click the link to review the publication )

EMBO J, 2013, 28;32(17):2377-91

PubMed: 23921550 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

J Hypertens, 2013, 31(2):303-11

PubMed: 23303355 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Onco Targets Ther, 2013, 6:1373-84

PubMed: 24124380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )
Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	NVO1WYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jQZWlEPTB;MD6wNlM{OSEQvF2=	NEjLfmpUSU6JRWK=
NCI-H720	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEP1VXVKSzVyPUCuNFI6OzhizszN	M2jtNHNCVkeHUh?=
KARPAS-45	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLjTWM2OD1yLkCzN\|cyKM7:TR?=	MY\TRW5ITVJ?
EW-3	M{K2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDLZWc5UUN3ME2wMlA1ODV4IN88US=>	MnjOV2FPT0WU
SBC-1	NGTCbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoOyTWM2OD1yLkC0OVgyKM7:TR?=	NUj4eVF3W0GQR1XS
NCI-H209	NIjnRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwMEW0OVMh\|ryP	NHf5WlRUSU6JRWK=
EoL-1-cell	NInMfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLXTWM2OD1yLkC2OVY6KM7:TR?=	NWTF[XV1W0GQR1XS
H9	NX;n[ndVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;qTWM2OD1yLkC2OlkzKM7:TR?=	MVfTRW5ITVJ?
AN3-CA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[3NmlEPTB;MD6wO\|k2OSEQvF2=	NHrrNodUSU6JRWK=
HH	M2HiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljlTWM2OD1yLkC4NFA6KM7:TR?=	MkHuV2FPT0WU
KU812	NH\TZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTBwMEiwOFMh\|ryP	NIf3ZoNUSU6JRWK=
DU-4475	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzEeo1oUUN3ME2wMlA5ODR5IN88US=>	M2jyPXNCVkeHUh?=
CTV-1	NH\tN\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2H2fWlEPTB;MD6wPFY1OSEQvF2=	M3LDPHNCVkeHUh?=
BV-173	NE\lfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTBwMEmwOlEh\|ryP	NW\hfJZ2W0GQR1XS
ES5	NILJc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\ZTWM2OD1yLkC5N\|Uh\|ryP	M365[3NCVkeHUh?=
G-402	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTBwMEm5PEDPxE1?	M4PsVHNCVkeHUh?=
MV-4-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTzOoNYUUN3ME2wMlExOzR5IN88US=>	M1XqcXNCVkeHUh?=
NB69	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXMTWM2OD1yLkGzOUDPxE1?	MnnIV2FPT0WU
EGI-1	M3T6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzQdm5KSzVyPUCuNVM2OzFizszN	MlX6V2FPT0WU
EW-18	M4PiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mny4TWM2OD1yLkG0NFc{KM7:TR?=	MlfTV2FPT0WU
ME-180	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O0XWlEPTB;MD6xOFY5OSEQvF2=	NETDUlNUSU6JRWK=
D-283MED	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXi3NW1tUUN3ME2wMlE1PzJ\|IN88US=>	M1ToRXNCVkeHUh?=
NB14	NUPTPYpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTMXXBKSzVyPUCuNVY1PDdizszN	NFHUN21USU6JRWK=
Ramos-2G6-4C10	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;CTWM2OD1yLkG2PVg{KM7:TR?=	MXTTRW5ITVJ?
NBsusSR	M1i5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DDOWlEPTB;MD6xO\|AyQSEQvF2=	NHrTNplUSU6JRWK=
LAMA-84	NVnGZ3dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTBwMUiwN\|Ih\|ryP	NIL4R4VUSU6JRWK=
NCI-H1581	M3nQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\UTWM2OD1yLkG4PVY3KM7:TR?=	M2\6NXNCVkeHUh?=
A204	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7OSnB4UUN3ME2wMlE5QTdizszN	M{LMRnNCVkeHUh?=
A549	NV7YUW03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLpV\|FKSzVyPUCuNVk2PSEQvF2=	M1K5OHNCVkeHUh?=
CAL-51	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHVNlZKSzVyPUCuNVk3PTFizszN	MlK5V2FPT0WU
NKM-1	NWLjW3ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mon1TWM2OD1yLkKwNFI6KM7:TR?=	MUPTRW5ITVJ?
LoVo	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\RTWM2OD1yLkKwNlAzKM7:TR?=	MVnTRW5ITVJ?
HAL-01	NFm5clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwMkCyPVch\|ryP	NVXJbWhYW0GQR1XS
HCC2218	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUC2Xm9{UUN3ME2wMlIxPjh6IN88US=>	M2PjdHNCVkeHUh?=
BEN	M1XnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{ThRmlEPTB;MD6yNVI6OyEQvF2=	MWPTRW5ITVJ?
LC-2-ad	M4TT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwMkKwPFQh\|ryP	NH\sUGxUSU6JRWK=
LXF-289	NVvlVVZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFf6cYlKSzVyPUCuNlUxPDFizszN	NXu5fodRW0GQR1XS
HGC-27	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3GPYxZUUN3ME2wMlI3PDF2IN88US=>	NEn6c3VUSU6JRWK=
LK-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP1TWM2OD1yLkK2PFI1KM7:TR?=	M1mzfHNCVkeHUh?=
CTB-1	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\CfFNTUUN3ME2wMlI4OjF3IN88US=>	M4TSd3NCVkeHUh?=
697	NYnOeZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\3OFVKSzVyPUCuNlc{PjdizszN	NW[y[HMyW0GQR1XS
ES7	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT1TWM2OD1yLkK3N\|g{KM7:TR?=	NFPrfHRUSU6JRWK=
MG-63	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPIbo5TUUN3ME2wMlI4PDB5IN88US=>	MWPTRW5ITVJ?
T47D	NXrU[Fg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2CyfWlEPTB;MD6yO\|Q4PSEQvF2=	NWrSdXlLW0GQR1XS
RPMI-8226	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGe5eoRKSzVyPUCuNlg2QDlizszN	M3;GcHNCVkeHUh?=
NCI-H292	NHvhT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPmWm5KSzVyPUCuNlkyPjRizszN	MmL0V2FPT0WU
HT	NX3zU5VKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEn3NIVKSzVyPUCuNlk{QCEQvF2=	Ml\NV2FPT0WU
A3-KAW	NE\1NGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwMkm3OEDPxE1?	M1i1XnNCVkeHUh?=
LB2241-RCC	NUCyfYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXDTWM2OD1yLkOwNVk5KM7:TR?=	MX;TRW5ITVJ?
BB65-RCC	M{DmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLsTWM2OD1yLkOwPFA2KM7:TR?=	NFnJTHZUSU6JRWK=
G-401	NETIPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3iZXpKSzVyPUCuN\|A6QDZizszN	NFizU29USU6JRWK=
TYK-nu	M3\EWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzxcpgyUUN3ME2wMlMyQDZ2IN88US=>	NFPkS4hUSU6JRWK=
NCI-SNU-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwM{KzN\|Eh\|ryP	NXvkU\|UxW0GQR1XS
CHL-1	NXvNb2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnwd5BTUUN3ME2wMlMzPzB\|IN88US=>	Ml23V2FPT0WU
P30-OHK	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{ToN2lEPTB;MD6zNlcxPSEQvF2=	MX\TRW5ITVJ?
PA-1	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTBTWM2OD1yLkOzOlE6KM7:TR?=	MVvTRW5ITVJ?
LB1047-RCC	M3PqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4f6TmlEPTB;MD6zOFA1PyEQvF2=	MWPTRW5ITVJ?
EM-2	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfUTWM2OD1yLkO0NVg5KM7:TR?=	NF;VS5FUSU6JRWK=
VA-ES-BJ	NIOxcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnGyTWM2OD1yLkO0NlY5KM7:TR?=	NWLOW29LW0GQR1XS
NCI-H520	NFTlZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\nUZRKSzVyPUCuN\|Q5OzRizszN	M1Xzd3NCVkeHUh?=
ECC10	NWLiVXJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrKTWM2OD1yLkO1NFM2KM7:TR?=	NIj1dZBUSU6JRWK=
LNCaP-Clone-FGC	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF6yR\|VKSzVyPUCuN\|U{OTRizszN	M3PDW3NCVkeHUh?=
ES8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TxTmlEPTB;MD6zOlU2OyEQvF2=	M3G3TXNCVkeHUh?=
HuO-3N1	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGX6SJZKSzVyPUCuN\|g{PzlizszN	MXzTRW5ITVJ?
L-363	NHjxPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTBwM{mwNlYh\|ryP	Ml3EV2FPT0WU
SK-LU-1	M{H5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXRe4lvUUN3ME2wMlM6OjB6IN88US=>	NHfXTJRUSU6JRWK=
MCF7	NWPjc2R7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\weI1wUUN3ME2wMlQxPTNizszN	NXvZUVZuW0GQR1XS
HuO9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnwNGpKSzVyPUCuOFA3PjdizszN	NFTHeFFUSU6JRWK=
BHT-101	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NECyOVZKSzVyPUCuOFA4QDdizszN	MYHTRW5ITVJ?
MZ2-MEL	M4XTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFm3XWdKSzVyPUCuOFA5QDJizszN	NYDqT5A1W0GQR1XS
NOS-1	NVyxc5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3L5NWlEPTB;MD60NVA4PCEQvF2=	MkjRV2FPT0WU
NEC8	M2P3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILNb5lKSzVyPUCuOFE3QTVizszN	NXnVO3EyW0GQR1XS
COR-L88	NYTDO3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjPe3B1UUN3ME2wMlQzOjZ5IN88US=>	NUfCNI1NW0GQR1XS
MFM-223	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HPdGlEPTB;MD60NlYyPyEQvF2=	MnP3V2FPT0WU
HSC-3	NEi4bZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3IRoU{UUN3ME2wMlQzQTB6IN88US=>	M3PTN3NCVkeHUh?=
OVCAR-5	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXXeWRXUUN3ME2wMlQzQTN\|IN88US=>	NEjtZmJUSU6JRWK=
MFE-280	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH62[2xKSzVyPUCuOFMxOzJizszN	MYLTRW5ITVJ?
KP-N-YS	M1nNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrNO5RKSzVyPUCuOFMxPyEQvF2=	MWrTRW5ITVJ?
EPLC-272H	MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDXTWM2OD1yLkSzNFc4KM7:TR?=	MmjPV2FPT0WU
KE-37	NUSyephnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF6xPJRKSzVyPUCuOFMzPDdizszN	NE[zZVhUSU6JRWK=
HuH-7	NWrsS29HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4D4XmlEPTB;MD60N\|M4OiEQvF2=	M3LFeHNCVkeHUh?=
CHP-212	M{HGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETwTpFKSzVyPUCuOFM3QTdizszN	M1:4d3NCVkeHUh?=
SK-MES-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1y2XWlEPTB;MD60N\|g1QCEQvF2=	NGnQPI9USU6JRWK=
SJSA-1	NWjTTXBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTBwNES1OVQh\|ryP	NELueplUSU6JRWK=
QIMR-WIL	M1[4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTBwNEWxOUDPxE1?	NVTMSYl3W0GQR1XS
ES4	NXrhPZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\rZmlEPTB;MD60OVM{PiEQvF2=	NH[1NVdUSU6JRWK=
TI-73	NYi5e3ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjHTWM2OD1yLkS1Olg3KM7:TR?=	NXrHc4ViW0GQR1XS
COLO-684	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwNEW3NlYh\|ryP	NFj4dmhUSU6JRWK=
GCIY	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTBwNEW3OVQh\|ryP	NY\kXJNpW0GQR1XS
JVM-3	NGjOe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEe3e4RKSzVyPUCuOFYzQTJizszN	NEX5OGRUSU6JRWK=
MPP-89	NVOwd4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjnSXhUUUN3ME2wMlQ3QTR5IN88US=>	NFn5U2RUSU6JRWK=
M14	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3KOXhiUUN3ME2wMlQ4OTdizszN	MmDLV2FPT0WU
SW962	NWLV[oxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHmSolKSzVyPUCuOFcyQSEQvF2=	NGfrfmFUSU6JRWK=
VM-CUB-1	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwNEeyPFYh\|ryP	NWm4Z2JVW0GQR1XS
A101D	NITDPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPYNmRKSzVyPUCuOFg6PjhizszN	NWTp[45UW0GQR1XS
DB	NEizcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD1TWM2OD1yLkWwNFIyKM7:TR?=	MUDTRW5ITVJ?
KNS-62	NF3BNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13yZmlEPTB;MD61NFU3QCEQvF2=	NVXzR5JDW0GQR1XS
NCI-H460	NFfPTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTvcZJKSzVyPUCuOVA2QTdizszN	NF3TRpBUSU6JRWK=
MDA-MB-361	NGTyXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrY[XhKSzVyPUCuOVA5PyEQvF2=	NHfZNWlUSU6JRWK=
DOK	NFvCclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\OTWM2OD1yLkWxN\|M{KM7:TR?=	NVjoXoN4W0GQR1XS
CAL-39	NUjMSIFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHKyZndKSzVyPUCuOVIzPjhizszN	MYXTRW5ITVJ?
HT-1080	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWS3VVZUUUN3ME2wMlUzPTR\|IN88US=>	NH7TTJJUSU6JRWK=
GR-ST	NHXZOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX30[ok4UUN3ME2wMlU{ODF3IN88US=>	MWjTRW5ITVJ?
J-RT3-T3-5	NWS1c3BOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfSTWM2OD1yLkWzNVk2KM7:TR?=	NX3TTG9SW0GQR1XS
NCI-H1793	M4jLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\2TWM2OD1yLkWzOFQ4KM7:TR?=	MXPTRW5ITVJ?
NCI-H1355	NYHxdmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;iOmlEPTB;MD61N\|g4QCEQvF2=	NVzWTJFLW0GQR1XS
YH-13	NFu3NYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDiTWM2OD1yLkW0PVM5KM7:TR?=	MX\TRW5ITVJ?
LOXIMVI	NVrFUGcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPETWM2OD1yLkW1NVI{KM7:TR?=	NWjY[5JGW0GQR1XS
ES1	M3vYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TqPGlEPTB;MD61OVUyQCEQvF2=	MnPRV2FPT0WU
GAMG	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTBwNUW2OVgh\|ryP	NX7nU5IxW0GQR1XS
SK-MEL-28	MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XsWmlEPTB;MD61OVkyKM7:TR?=	MkDKV2FPT0WU
KG-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TD[2lEPTB;MD61Olg5PCEQvF2=	MWLTRW5ITVJ?
HOS	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTBwNUexPVIh\|ryP	MlrvV2FPT0WU
PANC-08-13	NWK5V4RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH0dHlKSzVyPUCuOVc{QDlizszN	NUnOWplmW0GQR1XS
SW780	NWLqWZpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkP6TWM2OD1yLkW3OVk2KM7:TR?=	M3nUeHNCVkeHUh?=
MDA-MB-175-VII	MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHywXXVKSzVyPUCuOVc4PDFizszN	NEnS[3ZUSU6JRWK=
MSTO-211H	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwNUe3OVEh\|ryP	M2XmNXNCVkeHUh?=
ML-2	M2fwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwNUi0O\|gh\|ryP	MULTRW5ITVJ?
SCC-4	NFLSWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDNNoRKSzVyPUCuOVg2PDFizszN	M{PQW3NCVkeHUh?=
NCI-H1048	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofVTWM2OD1yLkW4OlQ2KM7:TR?=	MYjTRW5ITVJ?
NCI-H28	NX3VcnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPhd\|hiUUN3ME2wMlU5Pjd3IN88US=>	M1:3eHNCVkeHUh?=
BCPAP	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTkRWI4UUN3ME2wMlU5PzlzIN88US=>	MmXuV2FPT0WU
PC-14	NFXxendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS2dIFKSzVyPUCuOVg6PyEQvF2=	M3;UUXNCVkeHUh?=
OAW-42	NYW5eXh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTyepVZUUN3ME2wMlU6OTZ{IN88US=>	NXOwN3JKW0GQR1XS
IA-LM	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwNUm2NFkh\|ryP	NHLKTW1USU6JRWK=
Hs-578-T	M4HRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXtTWM2OD1yLkW5PFUyKM7:TR?=	NYDxTpNmW0GQR1XS
H4	NETwXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DYUmlEPTB;MD62NFA6PCEQvF2=	MnPCV2FPT0WU
HL-60	M33kW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HMemlEPTB;MD62NFM2OSEQvF2=	M2HiS3NCVkeHUh?=
NCI-H1437	NHrhWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUL0dpdbUUN3ME2wMlYxPjF7IN88US=>	MoDzV2FPT0WU
KGN	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXETGJKSzVyPUCuOlExPDlizszN	M2\0R3NCVkeHUh?=
NCI-H2452	MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr0VFlKSzVyPUCuOlE6OTdizszN	M1TRSHNCVkeHUh?=
BFTC-905	M3nPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPXOoJKSzVyPUCuOlIyOjZizszN	MoTsV2FPT0WU
CAMA-1	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3W1bmlEPTB;MD62NlE2OiEQvF2=	MmfFV2FPT0WU
SK-NEP-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTPTJNOUUN3ME2wMlYzPTB{IN88US=>	M4naXXNCVkeHUh?=
NCI-H522	NILieYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{f5bGlEPTB;MD62Nlk6OiEQvF2=	NX;ubVJbW0GQR1XS
SW1710	NX;BboFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDEVIRJUUN3ME2wMlY{OTZ5IN88US=>	MVjTRW5ITVJ?
RVH-421	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHIfYVKSzVyPUCuOlM3OzlizszN	M{ToPHNCVkeHUh?=
SK-MEL-2	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fRUmlEPTB;MD62OFE2OyEQvF2=	MlzUV2FPT0WU
KYSE-150	M2rTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTBwNk[xPFYh\|ryP	NIL3SJBUSU6JRWK=
MOLT-13	M4mxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwNk[1N\|ch\|ryP	Mli1V2FPT0WU
SK-OV-3	NUjZNZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwNkexPFch\|ryP	M{\lV3NCVkeHUh?=
IGROV-1	NFHBb\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwNke0OUDPxE1?	NHLhWVVUSU6JRWK=
MOLT-4	NXXKN\|czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTvNohxUUN3ME2wMlY4Pjh7IN88US=>	NYLtdJhFW0GQR1XS
MEL-HO	NXPjcWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHSXW9kUUN3ME2wMlY4PzV{IN88US=>	NGfvTFBUSU6JRWK=
MDA-MB-157	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nGXWlEPTB;MD62O\|gyKM7:TR?=	MYHTRW5ITVJ?
MN-60	NX7SbWpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPMRnNmUUN3ME2wMlY4QDR4IN88US=>	M4n1TnNCVkeHUh?=
EFO-27	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEn4UoNKSzVyPUCuOlc6PzlizszN	NYSwfY5QW0GQR1XS
HO-1-N-1	NYjYZWtkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jPZWlEPTB;MD62PFA3PCEQvF2=	MXvTRW5ITVJ?
TE-5	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTBwNki0NFUh\|ryP	M3nZUHNCVkeHUh?=
EW-22	M3rxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXE[pdKSzVyPUCuOlg1PDRizszN	NXnrdYdJW0GQR1XS
SW982	NEW4UGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;tV2lEPTB;MD62PFUxOSEQvF2=	MoPZV2FPT0WU
SF295	NH;aeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml62TWM2OD1yLk[4OVA4KM7:TR?=	NFqxdYlUSU6JRWK=
WM-115	M{D5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HhbWlEPTB;MD62PFkzPCEQvF2=	NIXSWYNUSU6JRWK=
COLO-800	NF\MS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7pTWM2OD1yLk[5PFE{KM7:TR?=	MorxV2FPT0WU
NTERA-S-cl-D1	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTTTWM2OD1yLkewNFY{KM7:TR?=	NFzBSlVUSU6JRWK=
NCI-H1648	NFvPdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDldpdZUUN3ME2wMlcxOTd\|IN88US=>	Ml3IV2FPT0WU
NB5	NHrvWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTBwN{CzNVkh\|ryP	M3HQWHNCVkeHUh?=
ATN-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvxVIJKSzVyPUCuO\|A2QSEQvF2=	Mnn3V2FPT0WU
NUGC-3	MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHqyfm5KSzVyPUCuO\|A3QTFizszN	M2\CZXNCVkeHUh?=
22RV1	NYTrRZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzDTWM2OD1yLkewO\|E4KM7:TR?=	M1LuSHNCVkeHUh?=
8305C	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwN{C3OVUh\|ryP	MUHTRW5ITVJ?
EFM-19	M2D0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\3TWM2OD1yLkewPFQ4KM7:TR?=	NV\XZo1PW0GQR1XS
PC-3	NES5TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHETWM2OD1yLkeyNlMh\|ryP	NVTBdIg{W0GQR1XS
C32	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIS1PXZKSzVyPUCuO\|I1QDRizszN	NYXubXRFW0GQR1XS
MC-IXC	M{TuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofhTWM2OD1yLkeyO\|E5KM7:TR?=	NVXEeWs4W0GQR1XS
OMC-1	M1zvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjDPYNKSzVyPUCuO\|I4OzhizszN	NGfDb2dUSU6JRWK=
HTC-C3	NXy1O\|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoraTWM2OD1yLkezNVczKM7:TR?=	NHHtZ4VUSU6JRWK=
RPMI-7951	NHTpdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGX4d49KSzVyPUCuO\|M2OzNizszN	NU\rRlFqW0GQR1XS
AsPC-1	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHpV4FKSzVyPUCuO\|M4QTVizszN	NHHS[lRUSU6JRWK=
CAKI-1	NYXnSnFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYC5UJJxUUN3ME2wMlc1PjJ7IN88US=>	MYTTRW5ITVJ?
MHH-PREB-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETu[o9KSzVyPUCuO\|Q4OzZizszN	NES5S4VUSU6JRWK=
HLE	NInBfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jHN2lEPTB;MD63OFg1PCEQvF2=	M{jGdHNCVkeHUh?=
A375	M2GxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrHUndKSzVyPUCuO\|UyQTNizszN	M{\wT3NCVkeHUh?=
RS4-11	M3\nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoryTWM2OD1yLke1PVQ{KM7:TR?=	MofBV2FPT0WU
U-2-OS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DDVWlEPTB;MD63OVk4KM7:TR?=	NHjMNYNUSU6JRWK=
NCI-H747	NYDSSHZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPXZoVKSzVyPUCuO\|U6QTFizszN	MUXTRW5ITVJ?
NCI-H1623	NF75NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDPRZB2UUN3ME2wMlc3OjZzIN88US=>	NWXiWVhuW0GQR1XS
DMS-273	M1TpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2S1ZWlEPTB;MD63OlkzOiEQvF2=	MoLFV2FPT0WU
PSN1	NEPlemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfqR4xDUUN3ME2wMlc4ODV5IN88US=>	NGe1bmlUSU6JRWK=
LU-99A	NFrpcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2ntOWlEPTB;MD63O\|Y1QSEQvF2=	NIW2RplUSU6JRWK=
CAL-12T	NFnnS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTXclFKSzVyPUCuO\|gxOjlizszN	Mm\PV2FPT0WU
KYSE-140	NWTwNVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\nS3JKSzVyPUCuO\|gyPjhizszN	M3jXdHNCVkeHUh?=
VMRC-RCZ	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzQTWM2OD1yLke4OFgzKM7:TR?=	MVrTRW5ITVJ?
Ca9-22	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLqPI9FUUN3ME2wMlc5PzN4IN88US=>	NEjXNm1USU6JRWK=
NCI-H1563	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwN{i5NlYh\|ryP	M4TjbXNCVkeHUh?=
NCI-H650	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HMTGlEPTB;MD63PVE1PCEQvF2=	Mn3FV2FPT0WU
DOHH-2	NUjPUnlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\ieXMyUUN3ME2wMlc6OzNizszN	NUjqOlVFW0GQR1XS
OE33	NHfnfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWm1[GRsUUN3ME2wMlc6QTF2IN88US=>	MoLlV2FPT0WU
CAL-62	NHXtUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTBwN{m5NlQh\|ryP	NVjjXmtQW0GQR1XS
NCI-H1770	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULSeI5QUUN3ME2wMlgxOjFizszN	NVy1N\|NJW0GQR1XS
SN12C	NWfadGZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjGSoVKSzVyPUCuPFA3PjhizszN	NEXkUFJUSU6JRWK=
HPAF-II	NEDU[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEniR21KSzVyPUCuPFA4QTRizszN	MmXlV2FPT0WU
SNU-423	NFjLWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTBwOEG0NlIh\|ryP	M4TkNnNCVkeHUh?=
A704	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwOEG3PVgh\|ryP	M3[1XXNCVkeHUh?=
OVCAR-4	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4X6OWlEPTB;MD64NVkyOSEQvF2=	MX;TRW5ITVJ?
NCI-H2347	NXzYXGhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwOEK0NFEh\|ryP	M2G0NXNCVkeHUh?=
OCUB-M	MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTBwOEK2O\|Uh\|ryP	NUDxbm5EW0GQR1XS
KYSE-450	NUK3XG1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwOEK3NlUh\|ryP	NWHidWFuW0GQR1XS
PFSK-1	NXvoUphvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HRd2lEPTB;MD64N\|A{QSEQvF2=	MYHTRW5ITVJ?
A431	NFHMZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTxTWM2OD1yLkizNVE3KM7:TR?=	M{GyXHNCVkeHUh?=
MHH-ES-1	M4XyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwOEO0OVch\|ryP	NYLs[XdCW0GQR1XS
HD-MY-Z	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW[zc5ZyUUN3ME2wMlg1ODl{IN88US=>	M2rvVXNCVkeHUh?=
RT-112	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTBwOES5N\|ch\|ryP	NH\OOHJUSU6JRWK=
KU-19-19	NULnZ5MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfOd2h{UUN3ME2wMlg2OTJzIN88US=>	NUHNendWW0GQR1XS
HCC1569	NGqxfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHxRmpKSzVyPUCuPFUzODdizszN	M2PMWnNCVkeHUh?=
RPMI-8866	M4[zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFno[WhKSzVyPUCuPFU5OjJizszN	M{PoXXNCVkeHUh?=
CAL-120	M4njPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELTcpBKSzVyPUCuPFYxPDFizszN	MnHEV2FPT0WU
CAL-33	NWD4dHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTBwOE[0PVUh\|ryP	M{X0VXNCVkeHUh?=
RKO	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2i3SGlEPTB;MD64OlgyPyEQvF2=	MWrTRW5ITVJ?
HCC1419	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P1NWlEPTB;MD64OlkzQCEQvF2=	MWjTRW5ITVJ?
CP50-MEL-B	NXrnendUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjzTWM2OD1yLki4N\|g1KM7:TR?=	NHzPXnZUSU6JRWK=
BPH-1	NHTPTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwOEizPVUh\|ryP	NYLNZ5RyW0GQR1XS
SF126	NIHqXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LHN2lEPTB;MD64PFcyPCEQvF2=	NGjlN2dUSU6JRWK=
BHY	NIXD[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3hTWM2OD1yLki4O\|M1KM7:TR?=	NEjQVnNUSU6JRWK=
BxPC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUT5flFmUUN3ME2wMlg5QDN\|IN88US=>	NV3qT5oyW0GQR1XS
ETK-1	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEm4U25KSzVyPUCuPFk{PzJizszN	MUXTRW5ITVJ?
NCI-H1573	M1W5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnqyTWM2OD1yLkmwNlI6KM7:TR?=	NF3VfZlUSU6JRWK=
C-33-A	NFPzdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHW4ZmFKSzVyPUCuPVA1PDJizszN	MkjQV2FPT0WU
UACC-893	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLITWM2OD1yLkmyPFU2KM7:TR?=	MV7TRW5ITVJ?
RXF393	NWDFNmR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjlU3I4UUN3ME2wMlkzQDl5IN88US=>	NI\HPJpUSU6JRWK=
MIA-PaCa-2	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwOUK5NlIh\|ryP	M{PVd3NCVkeHUh?=
HCC1806	M1fLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTBwOUOyOVYh\|ryP	Mkn1V2FPT0WU
DMS-114	NFrqc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTBwOUO2O\|ch\|ryP	NFrTc4xUSU6JRWK=
MOLT-16	M17TO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlL2TWM2OD1yLkmzPFQ2KM7:TR?=	NHvuRoJUSU6JRWK=
ACN	NELqUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\NellPUUN3ME2wMlk1Ojd5IN88US=>	M4jHN3NCVkeHUh?=
SNU-449	NIHrOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rnXmlEPTB;MD65OVkzPCEQvF2=	M4TnOHNCVkeHUh?=
A427	NVi4VIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTBwOU[xPVgh\|ryP	NIHMZ\|FUSU6JRWK=
DEL	M3zVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULEOWE6UUN3ME2wMlk3Pzd\|IN88US=>	Ml\RV2FPT0WU
NCI-H1792	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTJTWM2OD1yLkm3NVAyKM7:TR?=	Mo[1V2FPT0WU
A2058	M1npR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTBwOUezOkDPxE1?	NXrvcWptW0GQR1XS
SW13	NUCz[WNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnpS49zUUN3ME2wMlk5Ozl{IN88US=>	M{PKWXNCVkeHUh?=
T98G	NV3tT4V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfLblBKSzVyPUGuNFE{PjRizszN	NGHzT2RUSU6JRWK=
LU-134-A	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;3PFJKSzVyPUGuNFI3PzVizszN	NV\KTnp6W0GQR1XS
GI-ME-N	NUfvbGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHCTWM2OD1zLkCyPFI4KM7:TR?=	Mn3NV2FPT0WU
D-423MG	NIXyW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X0[mlEPTB;MT6wNlk3OyEQvF2=	Ml7yV2FPT0WU
PANC-03-27	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\mTWM2OD1zLkCzNVQyKM7:TR?=	NYO4UJpmW0GQR1XS
P12-ICHIKAWA	NEnX[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFwMEO0NFYh\|ryP	MUXTRW5ITVJ?
SCH	M2\EUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIj3fXNKSzVyPUGuNFM1PSEQvF2=	NVrwXlE{W0GQR1XS
D-566MG	M33abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTFwME[3NlYh\|ryP	NXKxSpRnW0GQR1XS
OS-RC-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7rV\|FKSzVyPUGuNFc6PCEQvF2=	Ml2xV2FPT0WU
KOSC-2	NHSw[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHNTWM2OD1zLkC4NFIyKM7:TR?=	NIDQ[5lUSU6JRWK=
SH-4	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDCc2VKSzVyPUGuNFg1OzFizszN	NEDwSoNUSU6JRWK=
786-0	NWXtPIhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwMEi5N\|Qh\|ryP	M3OyZ3NCVkeHUh?=
Mewo	NF\vXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFwMEmyOFgh\|ryP	MUPTRW5ITVJ?
AGS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3W4emlEPTB;MT6wPVQ2QSEQvF2=	NFHIR2FUSU6JRWK=
Daoy	NH7kS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnBTWM2OD1zLkC5OlI5KM7:TR?=	NIS2V3dUSU6JRWK=
SW48	NE\WdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFwMUC5NVEh\|ryP	M3PpR3NCVkeHUh?=
KYSE-180	NVPTe5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHnblcxUUN3ME2xMlEyODJzIN88US=>	NYrONYVvW0GQR1XS
NH-12	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwMUGyN\|ch\|ryP	MWDTRW5ITVJ?
BE-13	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2r1VWlEPTB;MT6xNVc2QSEQvF2=	MUHTRW5ITVJ?
ES3	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTFwMUOxO\|Eh\|ryP	Moe5V2FPT0WU
NCI-H1092	M{fScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWCwO3hYUUN3ME2xMlE{PCEQvF2=	NVnabmZVW0GQR1XS
NCI-H1755	NETBdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzzOlYzUUN3ME2xMlE{QTRzIN88US=>	NGDkVYZUSU6JRWK=
EKVX	NWDCW4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLLSmdHUUN3ME2xMlE1ODBzIN88US=>	NWCxSFFKW0GQR1XS
NB13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnETWM2OD1zLkG0OFUh\|ryP	MkHSV2FPT0WU
NCI-H2405	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fSfGlEPTB;MT6xOFU4PCEQvF2=	M2j6WHNCVkeHUh?=
LS-411N	M1GzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFwMUWwNVch\|ryP	NWXyU4JsW0GQR1XS
MDA-MB-453	NEj2OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPjSFV1UUN3ME2xMlE2PjJ2IN88US=>	M1zUcXNCVkeHUh?=
SCC-15	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnHV5BKSzVyPUGuNVY6PTZizszN	MoTlV2FPT0WU
C2BBe1	NHnhZ\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PFSWlEPTB;MT6xO\|A2PiEQvF2=	M1HLenNCVkeHUh?=
HT-144	NELjUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknLTWM2OD1zLkG3NFch\|ryP	MWjTRW5ITVJ?
HEC-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnvcno1UUN3ME2xMlE4PjJ5IN88US=>	NF7rbFRUSU6JRWK=
HCE-T	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTFwMUe5PFMh\|ryP	NWPGO5NVW0GQR1XS
IST-MEL1	NUTjR5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\HXG97UUN3ME2xMlE6ODh{IN88US=>	NEnU[FlUSU6JRWK=
Detroit562	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfLSIFKSzVyPUGuNVk1OzlizszN	MkC4V2FPT0WU
A4-Fuk	M2DaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4T3ZWlEPTB;MT6yNFQ1OSEQvF2=	MXHTRW5ITVJ?
HDLM-2	NV;u[HNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELsb5BKSzVyPUGuNlE{OjZizszN	NG\5ZphUSU6JRWK=
MKN7	NX;kTGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDBSJdKSzVyPUGuNlE4ODJizszN	MX7TRW5ITVJ?
MDA-MB-415	NYT1VmExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHqR2lKSzVyPUGuNlE4ODJizszN	MmjKV2FPT0WU
BT-20	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HkRWlEPTB;MT6yNlQ1PCEQvF2=	MlfzV2FPT0WU
NCI-H2030	NUXRdIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvYcmZiUUN3ME2xMlI1OTB4IN88US=>	M3nsbnNCVkeHUh?=
LS-123	NGTjVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWD5SnU3UUN3ME2xMlI1PzV\|IN88US=>	MlPTV2FPT0WU
SK-MEL-3	NHyyWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfJTWM2OD1zLkK0O\|c3KM7:TR?=	MX3TRW5ITVJ?
KS-1	NYHlRVl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULkRZQ4UUN3ME2xMlI2OTdzIN88US=>	MkXnV2FPT0WU
LU-65	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jD[GlEPTB;MT6yOVYxPiEQvF2=	NVj0fWxLW0GQR1XS
NCI-H596	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHiOolOUUN3ME2xMlI2QTJ7IN88US=>	MXLTRW5ITVJ?
KYSE-410	NIr2cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3kOHlKSzVyPUGuNlcxOTRizszN	MmP2V2FPT0WU
NCI-H2228	NEjI[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XxWGlEPTB;MT6yO\|E3PyEQvF2=	MWHTRW5ITVJ?
LN-405	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITMTldKSzVyPUGuNlgxOjFizszN	NXnldpYyW0GQR1XS
8505C	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jadGlEPTB;MT6yPFgzOyEQvF2=	MX;TRW5ITVJ?
BFTC-909	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;XTIhKSzVyPUGuNlk1OzRizszN	NXXBcZRPW0GQR1XS
OC-314	M1O2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwMkm5Nlkh\|ryP	M1fpTnNCVkeHUh?=
NMC-G1	M{jCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHZRmtmUUN3ME2xMlMyOTN3IN88US=>	MkDHV2FPT0WU
SKG-IIIa	NGH6XlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK0V4NKSzVyPUGuN\|E1OjhizszN	NUjpSlRHW0GQR1XS
GAK	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrQeIJlUUN3ME2xMlMyQDV6IN88US=>	NUnjV\|BRW0GQR1XS
D-263MG	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTFwM{K2OFEh\|ryP	MUTTRW5ITVJ?
NCI-H446	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTFwM{K5NFIh\|ryP	NVfhZW5wW0GQR1XS
TGBC1TKB	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFwM{K5PVgh\|ryP	MVPTRW5ITVJ?
GCT	MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTrfZRFUUN3ME2xMlM1OzR3IN88US=>	NIm3VnhUSU6JRWK=
COR-L23	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi3SYJKSzVyPUGuN\|Q5PDVizszN	NHvrNINUSU6JRWK=
TK10	M4jmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTFwM{W3PVch\|ryP	M1SwUXNCVkeHUh?=
ES6	NVXpflV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPJdJZqUUN3ME2xMlM3Ozd4IN88US=>	NGXMR5VUSU6JRWK=
SW1088	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW2eYoxUUN3ME2xMlM3PjF{IN88US=>	MVrTRW5ITVJ?
AM-38	M{DE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rYbWlEPTB;MT6zO\|E6QSEQvF2=	MXjTRW5ITVJ?
CHP-134	M2PPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfGVm1DUUN3ME2xMlM4QDR2IN88US=>	MYPTRW5ITVJ?
SW872	NUDnV25DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHiTmFKSzVyPUGuN\|g2PTVizszN	MX7TRW5ITVJ?
LB831-BLC	NG\RdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1H5RmlEPTB;MT6zPVA3PyEQvF2=	MUnTRW5ITVJ?
TE-12	NWf6PW5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYj0VIVTUUN3ME2xMlQxPjBzIN88US=>	M2\n[XNCVkeHUh?=
LCLC-97TM1	NUK4TWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXsTWM2OD1zLkSxNFQ3KM7:TR?=	MVjTRW5ITVJ?
HCT-116	NYm2Z25HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjjVWZKSzVyPUGuOFI5PTRizszN	MoHmV2FPT0WU
ALL-PO	M33Ce2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrwPGNKSzVyPUGuOFM4PzRizszN	NEDKemhUSU6JRWK=
EW-16	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTFwNEO4OFIh\|ryP	M2rHXHNCVkeHUh?=
NCI-H661	NYnaT\|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFwNES3O\|Uh\|ryP	M3z0bXNCVkeHUh?=
TE-8	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFwNEW1OkDPxE1?	MknRV2FPT0WU
TCCSUP	NYKySmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTFwNE[5OkDPxE1?	M1m1e3NCVkeHUh?=
SW1990	M3exb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4SzNWlEPTB;MT60O\|U{OyEQvF2=	MWnTRW5ITVJ?
UM-UC-3	M37nVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwNEe2O\|Uh\|ryP	MWPTRW5ITVJ?
HuP-T4	MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknNTWM2OD1zLkS4OlA4KM7:TR?=	NEjMfYRUSU6JRWK=
NCI-H1299	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XFVmlEPTB;MT61NFA5PiEQvF2=	MVvTRW5ITVJ?
RO82-W-1	NGPWTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLWTohnUUN3ME2xMlUzODhzIN88US=>	NIfMPY9USU6JRWK=
Becker	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H5N2lEPTB;MT61NlE5PyEQvF2=	MkfJV2FPT0WU
SNU-387	NEDNblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zjVmlEPTB;MT61NlI1OSEQvF2=	M33wT3NCVkeHUh?=
CAL-85-1	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXscXBKSzVyPUGuOVI2QTlizszN	M4DuR3NCVkeHUh?=
647-V	M4TtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHONo5KSzVyPUGuOVM5QCEQvF2=	NX7oeGFTW0GQR1XS
SBC-5	NUfoemx1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fUcGlEPTB;MT61OFU6OyEQvF2=	MkW1V2FPT0WU
NCI-H23	M{TYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TNPGlEPTB;MT61OVcyPCEQvF2=	Mni4V2FPT0WU
CGTH-W-1	NFvHfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTaZ\|B1UUN3ME2xMlU2QDF7IN88US=>	MXzTRW5ITVJ?
SK-N-FI	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HSSWlEPTB;MT61OVkxQCEQvF2=	M3PBfHNCVkeHUh?=
KM-H2	NWTQSHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTWb2tZUUN3ME2xMlU3PDd2IN88US=>	NXnXXpBLW0GQR1XS
KY821	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLDcngzUUN3ME2xMlU3PjF5IN88US=>	NETQOo5USU6JRWK=
RH-1	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFwNU[3OlIh\|ryP	NWDGeHlqW0GQR1XS
KYSE-270	M3fJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml6wTWM2OD1zLkW3OFI{KM7:TR?=	MXXTRW5ITVJ?
SF539	NH;me5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XrfmlEPTB;MT61O\|k3QSEQvF2=	MofCV2FPT0WU
JEG-3	NVi1SIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[4VlZwUUN3ME2xMlU5ODl2IN88US=>	NFLVZW5USU6JRWK=
SCC-25	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfTTWM2OD1zLkW4OFMzKM7:TR?=	NGXmNJRUSU6JRWK=
SW1573	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2X3dWlEPTB;MT62NFE2QCEQvF2=	M3HPXXNCVkeHUh?=
EW-1	NHywSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP6TWM2OD1zLk[xN\|UyKM7:TR?=	MkLjV2FPT0WU
YKG-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTNNXhbUUN3ME2xMlYyPDN6IN88US=>	MYfTRW5ITVJ?
EW-11	NF3oboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXK0OlBIUUN3ME2xMlYyPzRzIN88US=>	MWXTRW5ITVJ?
DJM-1	NF[2cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkn5TWM2OD1zLk[xPFI2KM7:TR?=	Mn;UV2FPT0WU
Calu-3	NFT5fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDtWYFKSzVyPUGuOlUzOTNizszN	NX3MSFR3W0GQR1XS
HT-3	NVj0cFRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDQVXo3UUN3ME2xMlY2PjZizszN	M3j4e3NCVkeHUh?=
NCI-H69	NWnWcFJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFwNkezOFMh\|ryP	NHrmTlhUSU6JRWK=
NCI-H2126	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo[0TWM2OD1zLk[3O\|k4KM7:TR?=	MXrTRW5ITVJ?
RPMI-2650	NH3CWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPsOGp6UUN3ME2xMlY5OzF5IN88US=>	MlTKV2FPT0WU
TE-6	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHoc21DUUN3ME2xMlcxQDd2IN88US=>	NFLiO5pUSU6JRWK=
MDA-MB-231	NVrEbldUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PlRWlEPTB;MT63NVk6OyEQvF2=	MWDTRW5ITVJ?
A2780	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TSZWlEPTB;MT63NlIxPyEQvF2=	Mlu5V2FPT0WU
GOTO	M2TGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnHcJNKSzVyPUGuO\|M2PiEQvF2=	MmHOV2FPT0WU
KYSE-70	MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW0cohHUUN3ME2xMlc1PDR{IN88US=>	MXrTRW5ITVJ?
GMS-10	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3MeGdKSzVyPUGuO\|Q3PjJizszN	MlOwV2FPT0WU
CaR-1	Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwN{S4NVIh\|ryP	NX\zZpJuW0GQR1XS
SW900	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFwN{S5PVMh\|ryP	MVTTRW5ITVJ?
BB49-HNC	M4Cye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTFwN{WxOlgh\|ryP	NXrxSFkxW0GQR1XS
SNB75	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jmfGlEPTB;MT63OVQ6OiEQvF2=	NFi0bGFUSU6JRWK=
SK-PN-DW	MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\IV2lEPTB;MT63OVY5OiEQvF2=	NVfyTZkxW0GQR1XS
5637	M1nv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHkTWM2OD1zLke3NlY5KM7:TR?=	MlPBV2FPT0WU
BT-474	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LlN2lEPTB;MT63PFE4OSEQvF2=	M1K3UXNCVkeHUh?=
KM12	NYewSmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7RTWM2OD1zLke5O\|QyKM7:TR?=	NUXOcGdQW0GQR1XS
COLO-680N	M2ToZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTENFhQUUN3ME2xMlgzOzhzIN88US=>	M1nl[3NCVkeHUh?=
Saos-2	NEjoeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHhUohKSzVyPUGuPFI1PDVizszN	NYPHdodsW0GQR1XS
CAL-54	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTFwOEOzNVMh\|ryP	MliyV2FPT0WU
U-118-MG	NInwSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnZfIJKSzVyPUGuPFQ3OjJizszN	MU\TRW5ITVJ?
TGBC24TKB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLUTWM2OD1zLki1OVAyKM7:TR?=	MV7TRW5ITVJ?
NCI-H2052	M1zodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXFeppKSzVyPUGuPFY1OSEQvF2=	NWPs[3JDW0GQR1XS
BB30-HNC	M4jn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHhTWM2OD1zLki2OFYzKM7:TR?=	MXvTRW5ITVJ?
KNS-81-FD	NVLPO21iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DENWlEPTB;MT64PVE3PSEQvF2=	MnLIV2FPT0WU
HN	NF\tWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFwOEm1OFUh\|ryP	M3H3dnNCVkeHUh?=
ACHN	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ntWmlEPTB;MT65NFc5PiEQvF2=	M4DkeHNCVkeHUh?=
HSC-2	M{HIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LyeGlEPTB;MT65NVA6PiEQvF2=	NXLv[4hJW0GQR1XS
HCC2998	M3SyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjMPJJKSzVyPUGuPVM{OjVizszN	MVHTRW5ITVJ?
HEL	M2jwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3wNY1KSzVyPUGuPVQyQDRizszN	NFnublhUSU6JRWK=
SW684	NXvYb4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLCTWM2OD1zLkm3N\|cyKM7:TR?=	Mm\NV2FPT0WU
NCI-H1693	NYnEOIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfBe3BKSzVyPUGuPVgxQDZizszN	MYjTRW5ITVJ?
8-MG-BA	M3rrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvCU\|BGUUN3ME2xMlk5OjFizszN	MWLTRW5ITVJ?
OVCAR-8	M33vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTJwMECyPVUh\|ryP	NUG0PYhzW0GQR1XS
DSH1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\hOWllUUN3ME2yMlAyPzd2IN88US=>	NXLDbGlXW0GQR1XS
KYSE-520	NWHPZop5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDyTWM2OD1{LkCyNFQ6KM7:TR?=	NH;lfZJUSU6JRWK=
GB-1	NUfobYZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzkTWM2OD1{LkCyOVc4KM7:TR?=	MmHlV2FPT0WU
RCC10RGB	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f3WWlEPTB;Mj6wOFg4OSEQvF2=	MlTSV2FPT0WU
SW954	NW[xOpI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJwMEWwN\|Yh\|ryP	MX\TRW5ITVJ?
IST-MES1	M3rLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fTd2lEPTB;Mj6wOVU3QCEQvF2=	NHHOUotUSU6JRWK=
AU565	M4PYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJwMEW5NFUh\|ryP	NUS4SXpVW0GQR1XS
CW-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TtTmlEPTB;Mj6wOlg4PSEQvF2=	NUG2b4RYW0GQR1XS
TE-1	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJwMEmzO\|ch\|ryP	M3Oy[3NCVkeHUh?=
KP-4	NGfEUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknZTWM2OD1{LkGwN\|EzKM7:TR?=	MoTjV2FPT0WU
SNU-C2B	M2i1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\KVYlKSzVyPUKuNVA5OjNizszN	MYXTRW5ITVJ?
NCI-H1395	M3zac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJwMUC5PFYh\|ryP	NE\MZZRUSU6JRWK=
CAS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;rOm1KSzVyPUKuNVE2PDZizszN	NX3JPWdUW0GQR1XS
NCI-H1155	NVfzdYozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnBV4pWUUN3ME2yMlIzPjlizszN	NWrNbFR[W0GQR1XS
SK-MEL-1	NF3YcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rUOGlEPTB;Mj6yPFE5OSEQvF2=	NUHoXVBKW0GQR1XS
KINGS-1	M2TD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJwM{CwPFgh\|ryP	MmjkV2FPT0WU
ESS-1	M1TidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{juT2lEPTB;Mj6zNFUyKM7:TR?=	M2i2XXNCVkeHUh?=
PANC-10-05	NXzEcpdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi5R2VMUUN3ME2yMlM4ODJ2IN88US=>	MXfTRW5ITVJ?
HT-1376	NEfiZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDjTWM2OD1{LkO4O\|A5KM7:TR?=	MknnV2FPT0WU
LS-513	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3P6NGlEPTB;Mj6zPFg4PCEQvF2=	MXLTRW5ITVJ?
KNS-42	M{SzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jkVGlEPTB;Mj6zPVExPSEQvF2=	MlfGV2FPT0WU
639-V	M37mWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJwNEK3OVgh\|ryP	MnqwV2FPT0WU
SJRH30	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXlZWhKSzVyPUKuOFUyPjFizszN	NHHLZoxUSU6JRWK=
SW1783	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXiTVBKSzVyPUKuOFcxPzhizszN	NWm0[Gg6W0GQR1XS
NB6	Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jYbmlEPTB;Mj60PFI5KM7:TR?=	MXXTRW5ITVJ?
SK-MEL-30	NEX1fopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDn[GVKSzVyPUKuOFg5OyEQvF2=	M{fWd3NCVkeHUh?=
HCE-4	NFS1fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorZTWM2OD1{LkS5OFAzKM7:TR?=	NGfRU29USU6JRWK=
NB10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37l[GlEPTB;Mj60PVQzQSEQvF2=	Mo[zV2FPT0WU
H-EMC-SS	NXPjXGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDWTGt5UUN3ME2yMlU1PjVizszN	M1XqNnNCVkeHUh?=
SK-HEP-1	NHTxd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnXOHRMUUN3ME2yMlU2OjN4IN88US=>	NXrQUWliW0GQR1XS
HCC1395	NHPtWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjpe\|ltUUN3ME2yMlU2PjV3IN88US=>	MXzTRW5ITVJ?
HuCCT1	NE[0SopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX31Z4p[UUN3ME2yMlU3OzlizszN	MmPRV2FPT0WU
SiHa	NW\RVGN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnaXVE5UUN3ME2yMlU5PzF7IN88US=>	MWfTRW5ITVJ?
EFO-21	M1PaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJwNUi3OlQh\|ryP	MmeyV2FPT0WU
NCI-H1666	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Ly[WlEPTB;Mj61PVA4PiEQvF2=	M{fxOHNCVkeHUh?=
UMC-11	NGLvWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHWb3FTUUN3ME2yMlU6QDZ6IN88US=>	M1WwTnNCVkeHUh?=
COLO-679	NUn2[W0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvHTWM2OD1{Lk[xNlM{KM7:TR?=	MnvkV2FPT0WU
A388	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XyXGlEPTB;Mj62OVI2OyEQvF2=	Mn\YV2FPT0WU
LB2518-MEL	NHvYSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTJwNkW0NFgh\|ryP	NIrQU\|RUSU6JRWK=
EW-13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;2VmlEPTB;Mj62PFc3QCEQvF2=	M3vUeXNCVkeHUh?=
MLMA	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPqdIpKSzVyPUKuOlg5PTZizszN	NIjuUVNUSU6JRWK=
HOP-92	NFHMV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDXOoNKSzVyPUKuO\|AyOSEQvF2=	MkTIV2FPT0WU
NOMO-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn[4TWM2OD1{LkexOFQzKM7:TR?=	M2faRnNCVkeHUh?=
NCI-H810	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nuWWlEPTB;Mj63NlE6QCEQvF2=	NHTMXmpUSU6JRWK=
769-P	NVPSPI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLNTWM2OD1{LkeyNlgh\|ryP	NWDsfVV{W0GQR1XS
SAS	NWLw[nExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fJSWlEPTB;Mj63OlUh\|ryP	NV\rRXFxW0GQR1XS
M059J	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTJwN{izNVgh\|ryP	NHHLdHdUSU6JRWK=
RD	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJwN{m0O\|Eh\|ryP	M4\xd3NCVkeHUh?=
GT3TKB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoX0TWM2OD1{LkizOFM{KM7:TR?=	MnHhV2FPT0WU
MZ7-mel	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmOxTWM2OD1{Lki2OVAzKM7:TR?=	Ml;lV2FPT0WU
KYSE-510	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDOTWM2OD1{Lki5OVA1KM7:TR?=	MkHTV2FPT0WU
NCI-N87	M2HldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvCeFVCUUN3ME2yMlkyQDB5IN88US=>	MVvTRW5ITVJ?
MKN1	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnX4TWM2OD1\|LkCwNVY{KM7:TR?=	NH\zNnJUSU6JRWK=
NCI-H2170	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfyfmNbUUN3ME2zMlAxPDVzIN88US=>	MnKzV2FPT0WU
OVCAR-3	NGrVfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTNwMEKxNVUh\|ryP	NHTTWmZUSU6JRWK=
KLE	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHhTWM2OD1\|LkC2PFEzKM7:TR?=	MXHTRW5ITVJ?
LB771-HNC	NYP2cWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTNwMEmzOFMh\|ryP	MmTLV2FPT0WU
MC116	NXXTZWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv5cY1tUUN3ME2zMlEyOTF{IN88US=>	M2LoZnNCVkeHUh?=
SCC-9	NXniTVVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTNwMUGzOlYh\|ryP	NGK4WG9USU6JRWK=
U031	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNwMUK0NlMh\|ryP	NVH4WXVlW0GQR1XS
LCLC-103H	NU\mXYp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK4TWM2OD1\|LkKzPFk1KM7:TR?=	M3m3NXNCVkeHUh?=
U-266	NIfBVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX3eYVQUUN3ME2zMlI4PjN\|IN88US=>	MXTTRW5ITVJ?
JVM-2	M4TBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvkeW1OUUN3ME2zMlMzOTZ2IN88US=>	NFTZeotUSU6JRWK=
UACC-257	NYrWdHVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTNwNE[0N\|Eh\|ryP	MknjV2FPT0WU
LB996-RCC	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHG1fXBKSzVyPUOuOFY2ODJizszN	M4HVV3NCVkeHUh?=
BT-549	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXFT5hsUUN3ME2zMlUxOjB7IN88US=>	Mly3V2FPT0WU
NCI-H526	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD0fZZ5UUN3ME2zMlU1OTV6IN88US=>	MVzTRW5ITVJ?
RH-18	NE\6N3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTNwNkG3PVgh\|ryP	MXHTRW5ITVJ?
SW626	NEXJOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TUN2lEPTB;Mz63NVEzQCEQvF2=	MYXTRW5ITVJ?
SK-N-AS	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\JOVNHUUN3ME2zMlc{OjR5IN88US=>	M4K1dXNCVkeHUh?=
IGR-1	M{DRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfKZ\|g2UUN3ME2zMlc1OjR6IN88US=>	M4LufHNCVkeHUh?=
NCI-H2291	M1nj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3WTWM2OD1\|Lke1N\|M3KM7:TR?=	MWPTRW5ITVJ?
NCI-H441	M3X5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTNwOEK0N\|Mh\|ryP	M32ydHNCVkeHUh?=
D-247MG	NWD5c5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrnXldKSzVyPUOuPFYxOzFizszN	MUDTRW5ITVJ?
COLO-320-HSR	M2nwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoOyTWM2OD1\|LkmxNlcyKM7:TR?=	NYHhUXFlW0GQR1XS
A253	M2LVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTNwOUG0N\|Yh\|ryP	NEfLS4ZUSU6JRWK=
HT55	NXLMZWVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDtNFV2UUN3ME2zMlkyPzd\|IN88US=>	MmrxV2FPT0WU
MZ1-PC	M1i0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzidnNKSzVyPUOuPVU5PjRizszN	Mn7mV2FPT0WU
RERF-LC-MS	M1X4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjmV45KSzVyPUOuPVY2OjVizszN	NHq4V4hUSU6JRWK=
SF268	M4fHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELxbmNKSzVyPUSuNVI5QDFizszN	MYDTRW5ITVJ?
RMG-I	NFW1d3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTBTWM2OD12LkKxOFU1KM7:TR?=	MX7TRW5ITVJ?
CFPAC-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWH5SXdUUUN3ME20MlIyPjh3IN88US=>	NEfPTHRUSU6JRWK=
S-117	NUDFOZlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;1cW9KSzVyPUSuNlIxOjRizszN	MnrnV2FPT0WU
NCI-H2122	M2\mUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvycnFKSzVyPUSuN\|A6OzFizszN	MXnTRW5ITVJ?
J82	NW\pR3pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXFTWM2OD12LkOzOFQyKM7:TR?=	NYL1SIpmW0GQR1XS
CAL-72	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTRwM{W0O\|ch\|ryP	M3nyd3NCVkeHUh?=
GP5d	NH\vWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET6WWFKSzVyPUSuOFEzQThizszN	NI[1T4VUSU6JRWK=
UACC-62	NF;EcYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rrWGlEPTB;ND60OlU1PSEQvF2=	MkTjV2FPT0WU
MS-1	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTRwNEmxNVUh\|ryP	NIfMdlFUSU6JRWK=
RCM-1	M{j2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPGTWM2OD12LkWyPVIh\|ryP	NG\EcGNUSU6JRWK=
IST-SL1	NFPX[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUG2UZBwUUN3ME20MlY2OzV7IN88US=>	MkmyV2FPT0WU
SW756	M2HObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfiR2VTUUN3ME20MlY6OTN3IN88US=>	M{fvWXNCVkeHUh?=
HCC38	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTRwN{GxPVch\|ryP	NUDVeIVWW0GQR1XS
YAPC	NWriUnJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37seGlEPTB;ND63NVMyOyEQvF2=	MV7TRW5ITVJ?
DK-MG	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTRwN{ixNVIh\|ryP	NVvQVGI3W0GQR1XS
HCC1937	M2Ozemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDoTlZKSzVyPUSuPFUyOjVizszN	M4TySXNCVkeHUh?=
OAW-28	M1PVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j0OWlEPTB;ND65NlQ{PSEQvF2=	NY\RSZl4W0GQR1XS
MEG-01	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGSwOJNKSzVyPUWuNFg{OjhizszN	MUTTRW5ITVJ?
GI-1	NWXEPGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\KcmtKSzVyPUWuNlM1QDZizszN	NWTEb3BDW0GQR1XS
FADU	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTVwMke4N\|ch\|ryP	MlPwV2FPT0WU
CAPAN-1	NGK2XopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHCTWM2OD13LkO5OFMzKM7:TR?=	MoPIV2FPT0WU
TGBC11TKB	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTVwNEW3PFYh\|ryP	MmTCV2FPT0WU
DBTRG-05MG	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITxZ2dKSzVyPUWuOVA2OiEQvF2=	NEfxO2NUSU6JRWK=
ONS-76	M2fIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\GZ4ZxUUN3ME21MlU2QDBzIN88US=>	MnvmV2FPT0WU
Ca-Ski	M1\s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTVwNkK1OlYh\|ryP	MnHoV2FPT0WU
COLO-741	NV\GXotIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTVwN{G5PVUh\|ryP	MVPTRW5ITVJ?
HT-29	NU\od5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTVwOEC0O\|Uh\|ryP	MVTTRW5ITVJ?
HCC1187	M4D5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTVwOEGwNFgh\|ryP	NV7i[o96W0GQR1XS
Capan-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zSRWlEPTB;NT65OVk6PCEQvF2=	MlfHV2FPT0WU
NCI-H630	M1nqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZwMUG0OFEh\|ryP	MVnTRW5ITVJ?
COLO-678	MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2H5VmlEPTB;Nj6xOVA6OiEQvF2=	NHfyWHpUSU6JRWK=
D-502MG	NWHQcJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PROmlEPTB;Nj6xO\|M{PiEQvF2=	NGHtcXhUSU6JRWK=
NB17	M3y4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLkOlZKSzVyPU[uNlQ6PDNizszN	NUTJfYxbW0GQR1XS
SK-MEL-24	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDhTWM2OD14LkK2OFkh\|ryP	MUnTRW5ITVJ?
NCI-SNU-5	M3noN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFW5PW9KSzVyPU[uNlcyOThizszN	MkDoV2FPT0WU
D-392MG	NUXDVoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTFTWM2OD14LkOzN\|k6KM7:TR?=	M1;Re3NCVkeHUh?=
A498	MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PyeWlEPTB;Nj60NFMxOiEQvF2=	M1q4T3NCVkeHUh?=
OCI-AML2	NUf1R4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTZwNEW0OFUh\|ryP	MoXvV2FPT0WU
HCC2157	M3zEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPE[FJKSzVyPU[uOFU3OTZizszN	MmXMV2FPT0WU
C3A	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXrZZZHUUN3ME22MlUzODB2IN88US=>	M4rHR3NCVkeHUh?=
NCI-H1650	NGnO[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrMTWM2OD14LkewOVIzKM7:TR?=	NWPr[JdEW0GQR1XS
DU-145	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTZwN{ewN{DPxE1?	M{PrWHNCVkeHUh?=
COLO-829	NF:3W\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTZwN{e4O\|Mh\|ryP	NH3PR5BUSU6JRWK=
LS-1034	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HDcWlEPTB;Nz6wOFQyOiEQvF2=	M1LLRXNCVkeHUh?=
HCC1954	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvYfmNqUUN3ME23MlQ5OTN2IN88US=>	NXjOdmdMW0GQR1XS
KURAMOCHI	NF7o[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTdwNEi1N\|Mh\|ryP	M1rwVXNCVkeHUh?=
Mo-T	NV\wNJdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLtZpFXUUN3ME23MlUyPDl6IN88US=>	Mlj4V2FPT0WU
OE19	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLETWM2OD15Lk[1OVA{KM7:TR?=	NGDiS2VUSU6JRWK=
COR-L105	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2myUWlEPTB;Nz63NVQzOSEQvF2=	Ml\jV2FPT0WU
NCI-H2342	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTdwN{G1NlEh\|ryP	MYLTRW5ITVJ?
U-87-MG	NInGU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jjSmlEPTB;OD6wN\|M{PCEQvF2=	NYjnSIQ6W0GQR1XS
MKN28	M4rISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRThwMUG1NVUh\|ryP	NXO2Z3lbW0GQR1XS
HT-1197	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnVcWRKSzVyPUiuNlU6ODdizszN	MYfTRW5ITVJ?
ChaGo-K-1	M{Lr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRThwM{SyOFUh\|ryP	MWHTRW5ITVJ?
NCI-H226	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrldoxKSzVyPUiuOFQ{OzFizszN	NV;yNWMzW0GQR1XS
NCI-H2029	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHBTpVzUUN3ME25MlA3PzV7IN88US=>	Mn3aV2FPT0WU
TE-11	NXK0OGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XwcWlEPTB;OT60OVU5QCEQvF2=	NH;YUmFUSU6JRWK=
ZR-75-30	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTlwOUK2N\|Qh\|ryP	NWX1Nm5MW0GQR1XS
SW837	M1LJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvZTWM2OD1zMD6yNlk{KM7:TR?=	MoO2V2FPT0WU
NCI-H1651	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXsTGdWUUN3ME2xNE4zOzJ4IN88US=>	MYDTRW5ITVJ?
NCI-H727	NWn3OoZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPEbHNKSzVyPUGwMlQ1QTVizszN	M2DoXHNCVkeHUh?=
NCI-H358	NFrNRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3qwWGlEPTB;MUCuPFM3PSEQvF2=	NHXHcJpUSU6JRWK=
NCI-H2087	NVHVT406T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPod4FZUUN3ME2xNU4xPDN2IN88US=>	MXLTRW5ITVJ?
FTC-133	NFPpU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj4d25KSzVyPUGxMlQxPTFizszN	MorUV2FPT0WU
LAN-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnlZ5lKSzVyPUGyMlEzPCEQvF2=	M{fLV3NCVkeHUh?=
NCI-H1838	NGfZRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2iwV2lEPTB;MUKuOVE2OSEQvF2=	MnX0V2FPT0WU
Calu-6	NX7TcXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTF2LkGwNlEh\|ryP	Mn7PV2FPT0WU
HCC70	NFfK[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HUUGlEPTB;MUSuOFUyKM7:TR?=	MUPTRW5ITVJ?
KARPAS-299	M{HjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonxTWM2OD1zNT6yNVU6KM7:TR?=	NVjjNZI4W0GQR1XS
CAL-27	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHuRVZjUUN3ME2xOU4{QDR\|IN88US=>	M4XKPXNCVkeHUh?=
NCI-H82	M1LTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPUfGpKSzVyPUG1MlU{OiEQvF2=	M3TzSHNCVkeHUh?=
no-10	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDRTWM2OD1zNT65N\|gh\|ryP	M2LNSXNCVkeHUh?=
U251	M1[4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvVTWM2OD1zNj6zOlc2KM7:TR?=	MofsV2FPT0WU
TE-9	M2TZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfjc4hKSzVyPUG3MlUyPjZizszN	MUjTRW5ITVJ?
TE-10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofVTWM2OD1zOT6wOlA4KM7:TR?=	MXjTRW5ITVJ?
COLO-824	M1noZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofSTWM2OD1{MD65Nlc3KM7:TR?=	M2HQPHNCVkeHUh?=
HuP-T3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDJTWM2OD1{MT6wO\|Q5KM7:TR?=	MlTnV2FPT0WU
KALS-1	M2W5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7TTWM2OD1{MT6xO\|Uh\|ryP	NHG0VmhUSU6JRWK=
L-428	NV;aR\|hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nGSmlEPTB;MkGuOFAyPiEQvF2=	NXrZU2ptW0GQR1XS
JAR	NGXJSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJzLkWwNkDPxE1?	MXnTRW5ITVJ?
DoTc2-4510	MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkL0TWM2OD1{Mz64OFc2KM7:TR?=	NIP5W4hUSU6JRWK=
ABC-1	Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7RSlhKSzVyPUK2Mlc6PTdizszN	MXHTRW5ITVJ?
MHH-NB-11	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPnTWM2OD1\|Mz6zOFY1KM7:TR?=	NVvqfppoW0GQR1XS
SW1463	Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTLTnZKSzVyPUOzMlk5OyEQvF2=	MUXTRW5ITVJ?
SW1417	NXv6Xm84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTN5LkC5OVIh\|ryP	NYHlVmxFW0GQR1XS
NB12	NUDvNplOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC5S\|RlUUN3ME2zPU41PjV3IN88US=>	MVPTRW5ITVJ?
NY	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;aTWM2OD12MT6zNlAyKM7:TR?=	Mn32V2FPT0WU
H1048	M4fac2Fxd3C2b4Ppd{BCe3OjeR?=	MX21NFAhdk1?	MX:3NkBp		NFO2bFVvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	M{n0cFI2PzN5NUSy
H86	MmDyRZBweHSxc3nzJGF{e2G7	MYW1NFAhdk1?	MkXhO\|IhcA>?		NVrjWJhIdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	MXSyOVc{PzV2Mh?=
H196	NGToenpCeG:ydH;zbZMhSXO\|YYm=	NXvrPFV2PTByIH7N	NHvENVI4OiCq		NWL5fJZXdmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	NUL2N\|ZTOjV5M{e1OFI>
H446	NFmyVnpCeG:ydH;zbZMhSXO\|YYm=	M3XMdlUxOCCwTR?=	Mmj1O\|IhcA>?		MV7ubIFv[2W\|IFHCWE0zPjQkgKPpcoR2[2WmIHHwc5B1d3Orcx?=	NHLQNlgzPTd\|N{W0Ni=>
TFK-1	NXizWoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3Lxd\|czKGh?	M{nHNGROW09?	MV7JR\|UxRTR5IH7N	NHPEVZMzPTF3MkK0OC=>
EGI-1	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC3NkBp	NHXicI5FVVOR	NHLTO4FKSzVyPUWzJI5O	NUXyU\|l4OjVzNUKyOFQ>
OCI/AML3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzSNE4zKM7:TR?=	MWW0PEBp		MVzlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	MU[yOFc{QTN7Mx?=
U937	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL1OHE3OC5{IN88US=>	MXW0PEBp		MUjlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	NGDGW3ozPDd\|OUO5Ny=>
MOLM13	NHzVTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTiNE4zKM7:TR?=	NWLiOId4PDhiaB?=		MWDlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	M2O2TVI1PzN7M{mz
MCF7	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS3R2diOjBibl2=	NYDuO\|FTPzJiaB?=	NEjlTo5HSlN?	NUPpTY1nemWmdXPld{B1cGViUFXMVFEudWWmaXH0[YQhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJk>	M3e0TVI1Pjh6MES2
TamR	NG\jfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PSemlEPTB;MUlihKlvVQ>?	MXGyOFQ2PzB4OR?=
MCF7-X	NWS0e3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\ad\|lKSzVyPUK0JI5O	NX3JPYpVOjR2NUewOlk>
T47D-tamR	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPQPHZKSzVyPUG5JI5O	Mn61NlQ1PTdyNkm=
293T	MojoSpVv[3Srb36gRZN{[Xl?	MkfTNlAhdk1?	MYmzJIg>		NFLUZ4NlcXO{dYD0d{BCc3RvbXXkbYF1\WRiVFnGMWlCKHO2YXLpcIl1gSxidILhcpNtd2OjdHnvckwh[W6mIHHjeIl3cXS7	MnPkNlQ{PjN2NEm=
SW620	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSwMlAxOS1zMN88US=>	NVmxPWQ3OjRiaB?=		M{HES4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYOgeIhmKGOxbnPlcpRz[XSrb36gdol{\XN?	M2LHc\|I1OzZ\|NES5
Huh7	NU\EVo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;LOVUuOTByIH7N	NVjFZ453OC1{NDDo	MYTEUXNQ	Mn\EbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	M1vKTFI1Ojl5M{Cw
Hep3B	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[zOU0yODBibl2=	M4\sR\|AuOjRiaB?=	MVPEUXNQ	Mke0bY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	M3nzWFI1Ojl5M{Cw
Huh7	Ml3XSpVv[3Srb36gRZN{[Xl?	MVWxNFAhdk1?	MWKxNkBp	NVnEVVJoTE2VTx?=	MnzrbY5lfWOnczDheZRweGijZ4pCpC=>	MkXxNlQzQTd\|MEC=
U87-MG	M1L0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{KzelczKGh?		NEXJfYpIUTVy4pEJQgKBkTd7IH7NxsA>	M2nrNVI1OjR7NkSw
L3.6pl	NHvZdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nSbFEh\|ryP	NFTFUIU4OiCq		MX7pcohq[mm2czD0bIUh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBDVVNvN{e3OlA4	MojZNlQzOzN\|OUm=
TE671	M2rF[mFxd3C2b4Ppd{BCe3OjeR?=	MkLuNUDPxE1?	M1\ncVQ5KGh?		NUfibHNtcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhSUKWLUezOy=>	M4[2O\|I1OTN\|MkG4
RD	M3TXOWFxd3C2b4Ppd{BCe3OjeR?=	M3vqNlEh\|ryP	MYe0PEBp		NGL6T3hqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	MoTwNlQyOzN{MUi=
RMS13	MmTFRZBweHSxc3nzJGF{e2G7	MkjxNUDPxE1?	NULWclNSPDhiaB?=		MWTpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	M2X0flI1OTN\|MkG4
RH30	Ml[yRZBweHSxc3nzJGF{e2G7	M{LVW\|Eh\|ryP	NVnwSmJCPDhiaB?=		MkW1bY5kemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgRWJVNTd\|Nx?=	M{PsSVI1OTN\|MkG4
Hep-2	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWWwMlAyNTFizszN	NYHS[lRoOTJvOU[gbC=>		M1vYfIlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MXyyOFExOzd2OR?=
SCC-9	M{f5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\YWlAvODFvMTFOwG0>	MXmxNk06PiCq		M1rRTIlv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MknGNlQyODN5NEm=
Hep-2	MV\GeY5kfGmxbjDBd5NigQ>?	NVW3NlNNOC5zL{CuOUDPxE1?	MWiyOEBp		Mn:1Zoxw[2u\|IH3UU3JEOSCjbnSgcXRQWkN{IHHjeIl3[XSrb36=	NUX2R2lTOjRzMEO3OFk>
SCC-9	MYnGeY5kfGmxbjDBd5NigQ>?	MVWwMlEwOC53IN88US=>	M1ixOlI1KGh?		MlPVZoxw[2u\|IH3UU3JEOSCjbnSgcXRQWkN{IHHjeIl3[XSrb36=	NFTo[HQzPDFyM{e0PS=>
PANC-1	NE\yWGlCeG:ydH;zbZMhSXO\|YYm=	MVG1NFAhdk1?	MVy0PEBp		M17vfZNmdnOrdHn6[ZMheGGwY4LlZZRq[yClYX7j[ZIh[2WubIOgeI8hemGmaX;0bIVz[XC7	MmLtNlM5QDZ{OUS=
RMG2	Mn3xRZBweHSxc3nzJGF{e2G7	MmXCNU0yODByIH7N	MV23NkBp	NWHzfYd5TkKV	MkjEbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	MX6yN\|YyPTZ\|MR?=
HAC2	MUXBdI9xfG:\|aYOgRZN{[Xl?	MoHKNU0yODByIH7N	NInPXGs4OiCq	M2\5PWZDWw>?	MmX4bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	NY\PdWtKOjN4MUW2N\|E>
HT-29	MnjHRZBweHSxc3nzJGF{e2G7	MoexNUDPxE1?	MkHYO\|IhcA>?		NF:w[YFifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	M2f3XVIyQTR7MUKx
DLD1	MUfBdI9xfG:\|aYOgRZN{[Xl?	M3HM[VEh\|ryP	MoHxO\|IhcA>?		NETBNVNifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	NIf5W2IzOTl2OUGyNS=>
HT-29	M1HOSmZ2dmO2aX;uJGF{e2G7	MmHJNUDPxE1?	NUnGfpZtPzJiaB?=		MYPpcoR2[2W\|IHH1eI9xcGGpeTD0c{Bkd26oZYKgZ5l1d3C{b4TlZ5Rqd25?	M4nFZVIyQTR7MUKx
DLD1	NWrYc4t5TnWwY4Tpc44hSXO\|YYm=	MYixJO69VQ>?	NXvWUWFJPzJiaB?=		NHXjbVFqdmS3Y3XzJIF2fG:yaHHnfUB1dyClb37m[ZIh[3m2b4Dyc5Rm[3Srb36=	NYTGdZZ7OjF7NEmxNlE>
Rh41	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\JZYhyUUN3ME2zNE44KG6P	NYHJOo83OjF\|M{e2O\|k>
Rh18	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHKZ3pKSzVyPUSxMlQhdk1?	NXrTfmtnOjF\|M{e2O\|k>
Rh30	M3LES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XJ[mlEPTB;MUSgcm0>	NX7GOFY4OjF\|M{e2O\|k>
BT-12	NWXwTllqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPOTWM2OD1{ND63JI5O	M1LhTlIyOzN5Nke5
CHLA-266	M4P2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjUeFI3UUN3ME2xMlEhdk1?	M2PjNlIyOzN5Nke5
TC-71	NGf2NWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWGwSnFwUUN3ME20Ok42KG6P	MVuyNVM{PzZ5OR?=
CHLA-9	NYryT\|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\0TWM2OD1zNT6zJI5O	MlT2NlE{Ozd4N{m=
CHLA-10	NHnP[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1i1VGlEPTB;Mz65JI5O	M1e1U\|IyOzN5Nke5
CHLA-258	NHT2Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fCSGlEPTB;MUCuOEBvVQ>?	NVvtVHVbOjF\|M{e2O\|k>
GBM2	NULVPW45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PxU2lEPTB;NECuO{BvVQ>?	MlvqNlE{Ozd4N{m=
NB-1643	NUGyTYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXX4N3o6UUN3ME2zN{45KG6P	M3O4bVIyOzN5Nke5
NB-EBc1	M1u4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPRSox4UUN3ME2yO{4yKG6P	MYmyNVM{PzZ5OR?=
CHLA-90	NH\VfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r4SGlEPTB;M{SuOUBvVQ>?	MnnRNlE{Ozd4N{m=
CHLA-136	MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TmUGlEPTB;MU[yMlYhdk1?	NH7k[FUzOTN\|N{[3PS=>
NALM-6	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrWZYtrUUN3ME2zNk46KG6P	NXP4epB6OjF\|M{e2O\|k>
COG-LL-317	NGPnO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTFwMzDuUS=>	MoH2NlE{Ozd4N{m=
RS4;11	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\NUWlKSzVyPUO1JI5O	M4fTVVIyOzN5Nke5
MOLT-4	M3LLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHvTWM2OD16Lk[gcm0>	NHXM[5czOTN\|N{[3PS=>
CCRF-CEM	NWTPNGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILYcItKSzVyPUSuNUBvVQ>?	Mk[1NlE{Ozd4N{m=
Kasumi-1	NFqzWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwNDDuUS=>	M3vWcVIyOzN5Nke5
Karpas-299	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2H5dmlEPTB;MkGuO{BvVQ>?	NVTEWZFEOjF\|M{e2O\|k>
Ramos-RA1	M1LrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRThwMjDuUS=>	MVuyNVM{PzZ5OR?=
H838	NU\mc3l{TnWwY4Tpc44hSXO\|YYm=	NYfwfYpkOSEQvF2=	M4fqZ\|Q5KGh?		NH7keHdqdmS3Y3XzJINmdGxiYYX0c5Bp[We7	M2nO[VIxOzZ2MUGz
H838	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUiwMVMh\|ryP	MYm3NkBp		NHfMS5dqdmS3Y3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CCjdYTvdIhi\3l?	M2LiTVIxODJ6OEW0
A549	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1X3fVAuOyEQvF2=	NXXQe5ZJPzJiaB?=		MWTpcoR2[2W\|IHfyc5d1cCCrbnjpZol1cW:wIHHu[EBifXSxcHjh[5k>	NVfaVWJmOjByMki4OVQ>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-mTOR / p-AKT / p-4EBP1 / p-P70S6K / p-PRAS40; PubMed: 24457069 Breast Cancer Res Western blots of 70% confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hours with AZD8055 (0 to 100 nM). Blots were probed with phospho- and total antibodies for mTORC1 and two signalling pathways. In both cell lines mTORC1 and mTORC2 s䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙 p-EGFR / EGFR; PubMed: 25654224 Int J Mol Sci PANC-1 cells were treated with AZD8055 for the indicated hours and EGFR (T/P), AKT (T/P) and ribosomal protein S6 (S6) (T/P) proteins were examined by western-blot; p-FOXO1 / FOXO1 / p-FOXO3a / FOXO3a ; PubMed: 25654224 Int J Mol Sci PANC-1 cells were transfected with FoxO1/FoxO3a siRNAs and treated with AZD8055 for 1 h, then AKT (T/P), FoxO1 (T/P), FoxO3a (T/P) and EGFR (T/P) proteins were examined by western-blot.	24457069 25654224
Immunofluorescence	p-4EBP1 / EIF4E / mTOR; PubMed: 24600487 Int J Clin Exp Med (C) Hoechst 33258 staining of Hep-2 cells after treatment with AZD8055 for 24 hours were shown. The cells were fixed and immunereacted with anti-mTOR antibody followed by incubation with Alexa 488-labeled secondary antibody (C-F). Images were taken by a c䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋à㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄堚،齃礤v�堞ﻮ᎒猢Wｾ᎒䨼Ą鹿齃殺獸W戀醙玛W戀ⶰ໯齃礤v 玚W玢Wⶰ໯﫰礌vtЉᔈැ鲬౴᥊疜犈፲Eo狜፲艘ᎂ艘ᎂ⩈̎䥠̌씢痗狠፲붖᎒i變ﱘ﫰﬐먙堘붖᎒狠፲i變ﱘ﫰먰堘ﱘ붖᎒�堞봆᎒릎堘붖᎒i꣩쯟巰痗ꣵ쯟巰痗Љ镴౴嶴痗Љ镨౴ᔈැ竗ᔈැ屷痗W竗尊痗 LC3B / p62 ; PubMed: 30337536 Cell Death Dis Immunofluorescence staining of U87 and U251 GICs, which treated by DMSO, AZD8055 (0.3 μM) and rapamycin (3 μM). The nuclei were stained with DAPI and the antibody against LC3B and p62. Images were captured by laser confocal microscope ( × 400), scale bar 䲧疝Ỵ疞	24600487 30337536
Growth inhibition assay	Cell viability ; PubMed: 29263324 Nat Commun Growth for the indicated cell lines was assessed after 72 h of treatment with AZD8055 (0–250 nM). Results are expressed as a percentage of cell number relative to the DMSO-treated control cells a.	29263324

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	- Collapse Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

- Collapse

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Water	Insoluble
	Ethanol	'3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Sapanisertib (MLN0128)

Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055